Roquefort Therapeutics plc (LON:ROQ – Get Free Report) traded down 6.9% on Friday . The stock traded as low as GBX 3.55 ($0.04) and last traded at GBX 3.68 ($0.05). 1,670,536 shares were traded during mid-day trading, an increase of 25% from the average session volume of 1,334,411 shares. The stock had previously closed at GBX 3.95 ($0.05).
Roquefort Therapeutics Price Performance
The firm has a market capitalization of £4.55 million, a PE ratio of -352.50 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07. The business’s 50 day moving average is GBX 4.06 and its two-hundred day moving average is GBX 4.06.
Roquefort Therapeutics Company Profile
Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Further Reading
- Five stocks we like better than Roquefort Therapeutics
- How to Calculate Options Profits
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What is the Shanghai Stock Exchange Composite Index?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- 3 Stocks to Consider Buying in October
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
